Pancreatic Cancer Research

ResearcherFujian Medical UniversityActive in the last 2 years

Ge Li

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-9030-884X; OpenAlex author ID A5100447673. Sources: OpenAlex.

Their work

Papers
7 (first author 0, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
21
Papers, trials and grants by year

2020: 3 papers · 2021: 1 paper · 2022: none · 2023: none · 2024: none · 2025: 2 papers · 2026: 1 paper

Papers 7

  1. Tumor-associated fibroblasts derived IBSP promotes gemcitabine resistance in pancreatic cancer by activating the ITGAV-PI3K/Akt pathway. Last author DOI 10.1016/j.bbadis.2026.168362↗
  2. SenExo-cCCT2 Reprograms Senescence Response and Anti-Tumor Immunity Following FOLFIRINOX Chemotherapy in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1002/advs.202508431↗
  3. Targeting CLK1/SRSF7 axis-dependent alternative splicing sensitizes pancreatic ductal adenocarcinoma to chemotherapy and immunotherapy. Co-author DOI 10.1016/j.drup.2025.101292↗
  4. SHCBP1 interacting with EOGT enhances O-GlcNAcylation of NOTCH1 and promotes the development of pancreatic cancer. Co-author DOI 10.1016/j.ygeno.2021.01.010↗
  5. Development and validation of novel nomograms for predicting the survival of patients after surgical resection of pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/cam4.2959↗
  6. Anterior gradient 2 is a novel pro-tumor factor in pancreatic cancer under NF-κB subunit RelA trans-regulation that can be suppressed by eugenic acid. Co-author DOI 10.1016/j.biopha.2020.110830↗
  7. LncRNA STXBP5-AS1 suppresses stem cell-like properties of pancreatic cancer by epigenetically inhibiting neighboring androglobin gene expression. Co-author DOI 10.1186/s13148-020-00961-y↗

Closest collaborators

The 21 strongest of 21 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Shi Chen · 6 shared papers, 2020–2025 · strength 0.84
  2. Yifeng Tian · 4 shared papers, 2020–2025 · strength 0.52
  3. Cheng‐Yu Liao · 3 shared papers, 2021–2025 · strength 0.51
  4. Zuwei Wang · 3 shared papers, 2021–2025 · strength 0.51
  5. Da Qian · 1 shared paper, 2026 · strength 0.43
  6. Haoxiang Zhang · 2 shared papers, 2025 · strength 0.40
  7. Shun‐Cang Zhu · 2 shared papers, 2025 · strength 0.40
  8. Yongding Wu · 2 shared papers, 2025 · strength 0.40
  9. Can Yang · 3 shared papers, 2020–2021 · strength 0.33
  10. Long Huang · 3 shared papers, 2020–2021 · strength 0.33
  11. Jiangzhi Chen · 2 shared papers, 2020 · strength 0.21
  12. Chengke Xie · 1 shared paper, 2025 · strength 0.20
  13. Chun Zhang · 1 shared paper, 2025 · strength 0.20
  14. Yu Pan · 1 shared paper, 2025 · strength 0.20
  15. Yan‐Ling Chen · 1 shared paper, 2020 · strength 0.12
  16. Qian Zhan · 1 shared paper, 2021 · strength 0.11
  17. Baiyong Shen · 1 shared paper, 2021 · strength 0.11
  18. Yao-Dong Wang · 1 shared paper, 2020 · strength 0.11
  19. Huatian Luo · 1 shared paper, 2020 · strength 0.11
  20. Zhixiang Jian · 1 shared paper, 2020 · strength 0.11
  21. Yaodong Wang · 1 shared paper, 2020 · strength 0.11

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.